Replies to post #108688 on Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

One company paid another several hundred million dollars for Amyvid. AMBS had to pay ICON 150000 to bring the test to market. Now, JN, the only financial analyst for the stock, notes that Lympro will not be a stand alone test ( I agree with that ) and has limited initial revenue, ( I agree with that ).